Physician profile
Michael S Swatts
NPI 1558331926
$59,007.31
in general payments reported to CMS, 2019-2025
19 companies · $5,922 in 2025
The $5,922 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $284 · 2021: $20K · 2022: $24K · 2023: $225 · 2024: $7,678 · 2025: $5,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,825.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $51,801.78 | 2021-2025 | M22, Optilight |
| Lumenis, INC | $4,500.00 | 2021 | |
| Alcon Vision LLC | $826.63 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $299.94 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $256.55 | 2023-2025 | Infuse, Blink Nutritears, Miebo |
| Oculus, INC. | $204.14 | 2024 | Na |
| Johnson & Johnson Vision Care, INC. | $188.87 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $150.82 | 2019-2023 | Cequa |
| Harrow Eye, LLC | $139.86 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $135.02 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $111.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $89.98 | 2019-2022 | |
| Dompe US, INC. | $85.06 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $68.20 | 2021-2022 | |
| Abbvie INC. | $49.58 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $46.06 | 2024 | Misight Contact Lens |
| Biotissue Holdings INC. | $20.43 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.93 | 2019 | |
| Shire North American Group INC | $15.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Swatts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.